Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cardiff Oncology, Inc.CRDF · Entity 6917 | Chief Medical Officer | June 16, 2025 | July 08, 2025 |
| Ernexa Therapeutics Inc.BTX · Entity 8278 | Chief Medical Officer | September 20, 2022 | September 21, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cardiff Oncology, Inc.
Report date June 16, 2025 · Filed July 08, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.86 · Expires 2035-06-16 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2025-06-16 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: (1) 150,000 of the Options vest on June 16, 2026 and 12,500 vest monthly for 36 months beginning on July 16, 2026, provided the Optionee on the vesting date continues to provide services to the Company or an Affiliate. |
Filing footnotes · ownership attribution and instrument terms
F1: (1) 150,000 of the Options vest on June 16, 2026 and 12,500 vest monthly for 36 months beginning on July 16, 2026, provided the Optionee on the vesting date continues to provide services to the Company or an Affiliate.
Ernexa Therapeutics Inc.
Report date September 20, 2022 · Filed September 21, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,163 |
Reported balance
After 2022-09-20 transaction · row 1
1 source rowRow 1 · 2022-09-20 · Exercise / conversion · Acquired 20,163 · Balance 20,163 F1: Each restricted stock unit converts into one share of common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 60,487 |
Reported balance
After 2022-09-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-09-20 · Exercise / conversion · Disposed 20,163 · Balance 60,487 F1: Each restricted stock unit converts into one share of common stock. F2: On September, 2021, the reporting person was granted 80,650 restricted stock units, vesting in four substantially equal installments beginning on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit converts into one share of common stock.
F2: On September, 2021, the reporting person was granted 80,650 restricted stock units, vesting in four substantially equal installments beginning on the first anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 20, 2022 Filed Sep 21, 2022 23:00 UTC | Ernexa Therapeutics Inc. BTX · Entity 8278 | Exercise / conversionRestricted Stock Units · Derivative | 20,163 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-034312 · form4.xml · derivative · entry 2 Sidhu Roger · CIK 0001884115 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,487 Underlying: Common Stock · 20,163 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock. F2 · derivative.exercise_date: On September, 2021, the reporting person was granted 80,650 restricted stock units, vesting in four substantially equal installments beginning on the first anniversary of the grant date. F2 · derivative.expiration_date: On September, 2021, the reporting person was granted 80,650 restricted stock units, vesting in four substantially equal installments beginning on the first anniversary of the grant date. Read SEC document |
| September 20, 2022 Filed Sep 21, 2022 23:00 UTC | Ernexa Therapeutics Inc. BTX · Entity 8278 | Exercise / conversionCommon Stock | 20,163 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-22-034312 · form4.xml · nonDerivative · entry 1 Sidhu Roger · CIK 0001884115 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,163 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit converts into one share of common stock. Read SEC document |
| March 11, 2022 Filed Mar 16, 2022 01:34 UTC | Ernexa Therapeutics Inc. BTX · Entity 8278 | GrantStock Option (Right to buy) · Derivative | 142,100 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001140361-22-009660 · form4.xml · derivative · entry 1 Sidhu Roger · CIK 0001884115 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,100 Underlying: Common Stock · 142,100 shares Expires 2032-03-11 F1 · derivative.exercise_date: The options vest and become exercisable over three years, with 25% of the options vesting on the one-year anniversary of the grant date and the remaining options vesting in 24 substantially equal monthly installments thereafter. Read SEC document |
| March 11, 2022 Filed Mar 18, 2022 01:00 UTC Amendment | Ernexa Therapeutics Inc. BTX · Entity 8278 | GrantStock Option (Right to buy) · Derivative | 142,100 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001140361-22-009980 · form4.xml · derivative · entry 1 Sidhu Roger · CIK 0001884115 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,100 Underlying: Common Stock · 142,100 shares Expires 2032-03-11 F1 · derivative.exercise_date: The options vest and become exercisable in 36 substantially equal monthly installments from the grant date. Read SEC document |
| September 20, 2021 Filed Sep 22, 2021 20:57 UTC | Ernexa Therapeutics Inc. BTX · Entity 8278 | GrantRestricted Stock Unit · Derivative | 80,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-21-032105 · form4.xml · derivative · entry 2 Sidhu Roger · CIK 0001884115 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,650 Underlying: Common Stock · 80,650 shares Expires 2031-09-20 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: The RSU Grant vests and becomes exercisable in four equal installments on September 20 of each of 2022, 2023, 2024 and 2025, provided that it shall vest in full immediately prior to a change in control (as defined in Dr. Sidhu's Executive Employment Agreement, effective September 20, 2021), subject to continued service through each vesting date. Read SEC document |
| September 20, 2021 Filed Sep 22, 2021 20:57 UTC | Ernexa Therapeutics Inc. BTX · Entity 8278 | GrantStock Option · Derivative | 161,300 | $0.00 Strike: $9.96 | $0.00 |
DisclosureSEC source: 0001140361-21-032105 · form4.xml · derivative · entry 1 Sidhu Roger · CIK 0001884115 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,300 Underlying: Common Stock · 161,300 shares Expires 2031-09-20 F1 · derivative.exercise_date: The option vests and becomes exercisable over four years, with twenty-five percent of the shares covered thereby vesting on September 20, 2022, and 1/36 of the remaining shares covered thereby vesting on the twentieth day of each calendar month from October 2022 through September 20, 2025, subject to continued service through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.